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Discussion
• Very preterm infants require mydriatic eye drops in preparation for retinopathy of 
prematurity (ROP) eye examination.
• In Australia and New Zealand,  ~1/3 premature infants/year are screened for ROP.  ~70% 
of screened infants do not have ROP.  ~25% of screened infants have stage 1 or 2 ROP.  
~5% of screened infants have stage 3 or 4 ROP.
• To establish the variation in mydriatic regimens in Australia and New Zealand.
• To estimate the frequency of adverse drug events after mydriatic administration.
• A Survey Monkey questionnaire was emailed to 
selected nursing staff at Neonatal Intensive Care 
Units (NICU) listed in the Directory of NICU within 
Australia and New Zealand, 2017.
• Nursing staff were asked to forward the survey to 
the target survey population (snowballing 
method).
• The target survey population was staff who 
administer the mydriatic eye drops for ROP eye 
examination.
• 46 neonatal nurses from all major regions 
in Australia and New Zealand participated 
in the survey.
• ~75% of participants prepared and/or 
administered mydriatic eye drops.
• Those that used 
phenylephrine/tropicamide used either 
0.5% or 1% tropicamide and always used 
2.5% phenylephrine.
• 90% of those that use Cyclomydril
administer it undiluted (phenylephrine 
2.5%/cyclopentolate 0.5%). 
• Those that prepared 
phenylephrine/cyclopentolate use a variety 
of concentrations (Figure’s 2 and 3.).
• The majority of nursing staff administer 
one (n=22) or two (n=16) standard drops 
for ROP eye examination.
• There was a wide range of reported 
adverse effects (Figure 1.).
• Nursing staff also reported seeing 
bradycardia, abdominal distension, death 
and seizure after mydriatic eye drop 
administration.
• Those that administered a microdrop used 
a needleless IV cannula or microdrop 
needle.
• There were eight different combinations of 
phenylephrine and cyclopentolate used in 
Australia and New Zealand NICU’s (n=33).
• Participants associate eye checks with significant harm, 
including NEC.
• There is a wide variety of mydriatic regimens in Australia and 
New Zealand NICU’s with a 37.5 fold unintentional difference in 
phenylephrine dosing.
• An appropriately powered multicentre study is required to establish an 
effective low dose for mydriasis.
• It is likely that unnecessarily high doses are being used and that 
may increase the risk for adverse effects.
• Over half of the nursing staff dilute eye drops into a lower 
concentration, suggesting that a new proprietary eye drop is 
needed.
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Figure 2.  Variation of cyclopentolate 
concentration in nurse prepared eye drops 
Figure 3.  Variation of phenylephrine 
concentration in nurse prepared eye drops
• There were four different combinations of 
phenylephrine and tropicamide used in 
Australia and New Zealand NICU’s (n = 9).
• The two commonest medication regimens 
were: phenylephrine 2.5%/cyclopentolate 
0.5% x 1 (n=12) OR 2 (n=6) standard drops.
• An appropriately powered randomised 
controlled trial is required to determine the 
incidence of adverse drug effects with the 
variation in mydriatic regimens, especially with 
the growing number of extremely low birth 
weight infants.  This study may also be able to 
identify if there is a subset of premature infants 
who are more susceptible to mydriatic induced 
adverse drug effects.
